DeutschNewstral
Article
Ccalcalistech.com on 2018-07-24 12:08
Gastro treatment firm RedHill wants to raise $117 on Nasdaq
Related news
Israel’s Redhill Biopharma gets green light for experimental COVID-19 treatmenttimesofisrael.com- CGamida cell downprices shares to raise $50 million in Nasdaq IPOcalcalistech.com
RedHill Biopharma's coronavirus treatment shows improvement in patientsbizjournals.com
SEC Approves Nasdaq Rule Change Allowing Direct Listings with a Capital Raise (Update)jdsupra.com- MAthenex's stock to debut on the Nasdaq after pricing IPO to raise $66 millionmarketwatch.com
- Fort Lauderdale company begins trading on Nasdaq, aims to raise $200M for real estate SPAC dealbizjournals.com
- SEC Approves Nasdaq Rule Change Allowing Direct Listings with a Capital Raisejdsupra.com
- Nasdaq Receives Approval for Rule Change Providing More Flexibility for Direct Listings with Capital Raisejdsupra.com
- Israel’s Redhill Biopharma launches US sales of anti-bacterial drugtimesofisrael.com
- RedHill seeks FDA nod for drug to eradicate gut infectiontimesofisrael.com
- MRedHill Biopharma reports positive results from mid-stage trial of irritable bowel syndrome treatmentmarketwatch.com
- North Carolina pharma RedHill to study coronavirus treatment on patients in USbizjournals.com
- RedHill gets FDA nod for drug to eradicate gut infectiontimesofisrael.com
- RedHill Biopharma shows positive data on treatment for severe Covid patientsbizjournals.com
- North Carolina pharma RedHill to have second drug tested for potential Covid-19 treatmentbizjournals.com
- SEC Approves Anticipated Nasdaq Board Diversity Rulesjdsupra.com
- SEC Approves NASDAQ Board Diversity Rulesjdsupra.com
- SEC Approves Nasdaq Board Diversity Rulejdsupra.com
- SEC Approves Nasdaq Board Diversity Rulesjdsupra.com